Intratympanic Gentamicin for Intractable Meniere's Disease: 5-Year Follow-up

2003 ◽  
Vol 32 (05) ◽  
pp. 288 ◽  
Author(s):  
Jason Atlas ◽  
Lorne S. Parnes
Keyword(s):  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Intratympanic Gentamicin ◽  
Ménière's Disease

Hearing results following intratympanic gentamicin perfusion for Ménière's disease

2008 ◽  
Vol 123 (4) ◽  
pp. 379-382 ◽  
Author(s):  
E Kyrodimos ◽  
I Aidonis ◽  
A Sismanis
Keyword(s):  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Speech Discrimination ◽  
Menière's Disease ◽  
Hearing Results ◽  
Intratympanic Gentamicin ◽  
Ménière's Disease

AbstractObjective:To evaluate hearing results following intratympanic gentamicin perfusion in patients with Ménière's disease.Materials and methods:Middle-ear perfusion of 0.4 ml of gentamicin 40 mg/ml solution was performed in Ménière's disease patients who had previously failed to respond to other medical treatment.Results:Between May 1999 and November 2005, 22 patients (mean age 58.5 years) underwent intratympanic gentamicin perfusion. Mean follow up was 30 months. At the first post-perfusion visit (four to six weeks following perfusion), three of the 22 patients (13.63 per cent) had a pure tone average improvement of at least 10 dB, 15 (68.18 per cent) showed no change and four (18.18 per cent) demonstrated a decrease in hearing of more than 10 dB. Regarding speech discrimination scores, one patient (4.54 per cent) exhibited an improvement of at least 15 per cent, 15 (68.18 per cent) showed no change and six (27.27 per cent) showed a decrease of at least 15 per cent. After long-term follow up (12–40 months following perfusion), 10 patients (45.45 per cent) showed stable hearing, and 12 (54.54 per cent) exhibited a pure tone average decrease of more than 10 dB. Six patients (27.27 per cent) showed a speech discrimination score decrease of at least 15 per cent, while 16 (72.72 per cent) had no change. Complete cessation of vertigo was reported by 20 of the 22 patients (90.9 per cent), while two (9.09 per cent) reported episodic vertigo spells.Conclusion:Intratympanic gentamicin perfusion provides effective control of vertigo in patients with Ménière's disease. However, significant hearing loss may occur immediately after perfusion; therefore, this treatment should be considered only for patients whose hearing has already been affected by the disease.

Recurrent Vertigo after Intratympanic Gentamicin for Ménière’s Disease: Long-term Follow-up of Two Regimens

2013 ◽  
Vol 149 (2_suppl) ◽  
pp. P109-P109
Author(s):  
Augusto P. Casani ◽  
Niccolò Cerchiai ◽  
Iacopo Dallan ◽  
Elena Navari ◽  
Stefano S. Franceschini
Keyword(s):  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Intratympanic Gentamicin ◽  
Long Term Follow Up ◽  
Ménière's Disease

scholarly journals Efficacy and Durability of Intratympanic Gentamicin Treatment for Meniere's Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Yafeng Guan ◽  
Divya A. Chari ◽  
Yu-Hsi Liu ◽  
Steven D. Rauch
Keyword(s):  
Treatment Success ◽  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Duration Of Symptoms ◽  
Intratympanic Gentamicin ◽  
Ménière's Disease

Objective: To study the success of intratympanic gentamicin (ITG) treatment in reducing vertigo attacks in Meniere's disease (MD) and the value of the Halmagyi head thrust test (HTT) in predicting treatment durability.Study Design: Retrospective cohort study.Setting: Tertiary care vestibular clinic.Patients: Unilateral MD patients treated with ITG from 2006–2019 with ≥6 months follow-up.Main Outcome Measures: Demographics, audiometric data, subjective symptomatology, and HTT results were collected. Treatment success was defined as sufficient symptom relief. Treatment failure indicated vertigo control of less than 6 months duration. Treatment relapse indicated vertigo recurrence after 6 months.Results: Of 255 patients, treatment success, failure, and relapse occurred in 226 (88.6%), 29 (11.4%), and 121 (47.1%) patients, respectively. 48 (18.8%) patients who failed to respond or relapsed underwent labyrinthectomy. Mean follow-up time was 3.7 yrs (range 0.5–12.8). After ITG treatment, 25% patients reported worse hearing; mean pure tone average (PTA) increased by 18.6 ± 11.3 dB and mean word recognition score (WRS) decreased by 33 ± 21%. Of the 148 patients with negative pre-treatment HHT, 103 (69.6%) converted to positive after ITG treatment. Mean time-to-relapse in the converted and non-converted HTT cohorts was significantly different (49.7 vs. 27.0 months, p = 0.009) even after adjusting for gender, age, laterality, duration of symptoms, and number of ITG treatments. There were no significant differences between the two groups in hearing outcomes or subjective symptoms (e.g. lingering disequilibrium).Conclusions: ITG treatment effectively reduces the number of vertigo attacks in MD. HTT is valuable in predicting durability of treatment benefit.

Intratympanic gentamicin treatment for unilateral Ménière's disease: long-term follow up of a proven regime

2012 ◽  
Vol 127 (1) ◽  
pp. 20-24 ◽  
Author(s):  
J Wasson ◽  
N Upile ◽  
A Pfleiderer
Keyword(s):  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Intratympanic Gentamicin ◽  
Long Term Follow Up ◽  
Ménière's Disease

AbstractObjective:To determine the long-term efficacy of a fixed-dose intratympanic gentamicin treatment regime in controlling unilateral Ménière's disease.Methods:Pfleiderer (1998) published two-year follow-up results for a series of 16 patients treated with a 4-day, 12-dose intratympanic gentamicin regime for unilateral Ménière's disease that was refractory to medical treatment. In 2010, a long-term telephone follow up (mean 17 years and 3 months) of this same cohort was conducted to determine long-term vertigo control. Of the 16 patients, 13 were eligible for the long-term follow up.Results:At 2 years' follow up, all 16 patients experienced substantial control of vertigo, with complete control achieved in 87 per cent of cases. At the long-term follow up, 9 of the 13 eligible patients were contactable, and all reported complete control of vertigo.Conclusion:Fixed-dose intratympanic gentamicin controlled symptomatic unilateral Ménière's disease in both the short and long term.

Vestibular function at the end of intratympanic gentamicin treatment of patients with Ménière's disease

2005 ◽  
Vol 15 (1) ◽  
pp. 49-58
Author(s):  
Nicolas Perez ◽  
Julio Rama-Lopez
Keyword(s):  
Time Constant ◽  
Vestibular Function ◽  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Bedside Examination ◽  
Intratympanic Gentamicin ◽  
Ménière's Disease

The aim of this study is to analyze the effects of intratympanic gentamicin injections on vestibular function in 33 patients with unilateral Meniere's Disease (according to AAO-HNS guidelines 1995) that had been unresponsive to medical therapy for at least one year. In such patients, the results of bedside examination of vestibular function vestibular examination is compared to those from laboratory tests. Intratympanic gentamicin injections (27 mg/ml) were performed at weekly intervals until symptoms or signs of vestibular hypofunction developed in the treated ear. Vestibular function was evaluated in two different rotatory chair tests. The parameters that were specifically considered were the time constant of the vestibulo-ocular reflex (VOR) after impulse rotation with a peak chair velocity of 100°s-1, and the phase and gain of the VOR after the sinusoidal harmonic acceleration (SHA) test with a peak chair velocity of 50°s-1. After treatment, both the time constant of the VOR after rotation towards the treated side and the gain in the SHA test were significantly reduced. These reductions were in accordance with the number of additional signs observed upon bedside examination at the end of the treatment. The changes observed in the VOR correlate well with the results of bedside examination of vestibular function, which in turn reflects the damage induced by intratympanic gentamicin injection.

Intratympanic gentamicin in monolateral Meniere’s disease: our experience

2005 ◽  
Vol 263 (3) ◽  
pp. 271-275 ◽  
Author(s):  
Giulia Bertino ◽  
Domenico Durso ◽  
Marco Manfrin ◽  
Luca Casati ◽  
Eugenio Mira
Keyword(s):  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Intratympanic Gentamicin ◽  
Ménière's Disease
Sign in / Sign up

Export Citation Format

Share Document